The background to finerenone and the FIDELIO CKD trial was covered in a post on the 11th of July. Last week, there was a coordinated presentation at the American Society of Nephrology Kidney Week and a publication in the New England Journal of Medicine of the details of the the FIDELIO CKD. In a nutshell,… Continue reading The fine details of the finerenone Fidelio CKD trial – A new drug to slow CKD
The much awaited outcome of the DAPA-CKD (Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease ) trial was presented on 30 August 2020 at the ESC (European Society of Cardiology) Congress 2020 by Prof H. Heerspink. Dapagliflozin is an SGLT2 ( Sodium-Glucose Co-transporter 2) inhibitor being used,so far, in the treatment of type… Continue reading Ground breaking results from key trial : DAPA CKD
In Mauritius, there is no real culture of critically appraising medical research literature and even less of undertaking clinical research. I must admit that I also share that diffidence towards medical research. It's never too late to learn however! There is an interesting and free course held by the Indian Society of Nephrology every weekend… Continue reading Online introductory and advanced course in research methodology by the Indian Society of Nephrology
The Summary A Chinese led research team say a blood test – called PanSeer – detects cancer in 95% of asymptomatic individuals who later receive a diagnosis. “We demonstrated that five types of cancer can be detected through a DNA methylation-based blood test up to four years before conventional diagnosis,” the team writes in the… Continue reading ‘Liquid Biopsy’ Detects Cancer Years Before Symptoms
Two newsworthy news in the fight against Covid-19 from the UK yesterday. Beta Interferon First, there was a small double blind placebo-controlled RCT using a novel inhaled formulation of interferon beta SNG001 in hospitalised COVID-19 patients. The trial recruited 101 patients from 9 specialist hospital sites in the UK. Patient groups were evenly matched in… Continue reading UK Covid-19 Double Breakthrough
Covid-19 infections keep rising inexorably. So do Covid-10 publications. Impossible to keep up with the data overload but the following articles have caught my eye. If you have read some other noteworthy ones, do let me know. My selection includes a considered opinion on the management of acute respiratory distress syndrome ARDS, promising Phase 1… Continue reading Covid-19 Digest 19 July
The eagle eyed amongst you may have noticed a little feature on the front page of this website: Mauritius in Scientific Publications. This is where the most recent five publications on Pubmed is listed. When I set it up a few weeks ago, I didn't expect new items to appear that often. There has actually… Continue reading First Covid-19 Publications Made in Moris!
Big announcement from Bayer on Thursday 9 June. Are we on the verge of a major step forward in the pharmacological fight against diabetic nephropathy? We all know diabetic nephropathy (DN) is by far the most common cause of end-stage renal disease in Mauritius and worldwide. The inhibition of the renin-angiotensin-aldosterone system (RAAS) has been… Continue reading A Fine Renal Breakthrough?
I do admit I like Wikipedia and I use it for medical information too. Surfing the SARS-CoV-2 page led me to the Nextstrain page. What a discovery it was! I have spent hours navigating the site, decrypting the colourful intricate diagrams and playing round with the interactive settings including a play button for the animation of genomic… Continue reading Real-time tracking of pathogen evolution
In the search for a treatment for COVID-19, attention has turned to preexisting drugs in the hope to reduce the lead time in finding a cure. Hydroxychloroquine (HCQ), chloroquine (CQ) and macrocodes (MC) are all known to have antiviral effects (first two through endosomal acidification) in other viral diseases and there were promising results in… Continue reading Hydroxychloroquine for Covid-19: Review of the Literature so far